Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
about
miR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaIncreased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockadeArsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.Glutathione S-conjugates as prodrugs to target drug-resistant tumors.Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).Effects of three different types of antifreeze proteins on mouse ovarian tissue cryopreservation and transplantation.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction.Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.Inorganic arsenic inhibits the nucleotide excision repair pathway and reduces the expression of XPCDistinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.Effects of antifreeze proteins on the vitrification of mouse oocytes: comparison of three different antifreeze proteins.Malignant mesothelioma: development to therapyEndoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells.BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state
P2860
Q28397829-656473C1-0D42-4196-BCD6-D6A13EE7E9EFQ28539684-067B08C4-5B46-4269-8665-5D7270EA8C78Q33726127-C688F414-A8D9-4E9E-8AB6-9BDBBC4A33EFQ34024771-224555C5-F807-4A73-8D3A-33DDCA4F9EADQ34970431-98BC862A-1EAE-40A5-87AE-98A9BE79A5BAQ35566786-0EC7AFA5-5392-4D1C-B156-9C6FA4BF6CFEQ36081391-CBE29DDF-1BFC-40A9-B75C-1A15A4CE73D3Q36662001-43E30A5E-8250-4F3F-996F-7C0AF60DCC18Q37022265-9818EF9F-3C30-43C3-945F-DAC07482393FQ37317264-7E5D2125-C867-4B04-AF7B-63B1E5400408Q37493010-992D92D5-F265-4614-B0C2-38ADF5102211Q38288940-65E7343C-D3AA-4810-830C-C34A160CAF60Q38707939-61C514D6-369A-4E1D-AB3D-580C4040EC6AQ38922208-EF8E0DAF-4485-4ECE-A59E-57528729D1DFQ41600507-AA4F0224-3FC9-4F40-8771-D5FFA887EFFBQ41967712-B3E5039E-C8E3-44A9-8543-8EDED7907180Q42704056-CD9829AF-56B4-4A2A-AC2F-216A29A24BE7Q57983113-0F2B28FC-CE94-451B-A0DF-5C6080098B3A
P2860
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Synergistic anticancer activit ...... NA double-strand break repair.
@en
Synergistic anticancer activit ...... NA double-strand break repair.
@nl
type
label
Synergistic anticancer activit ...... NA double-strand break repair.
@en
Synergistic anticancer activit ...... NA double-strand break repair.
@nl
prefLabel
Synergistic anticancer activit ...... NA double-strand break repair.
@en
Synergistic anticancer activit ...... NA double-strand break repair.
@nl
P2093
P50
P1476
Synergistic anticancer activit ...... NA double-strand break repair.
@en
P2093
Claudia Karnthaler-Benbakka
Franziska Ferk
Mir Alireza Hoda
Siegfried Knasmüller
P304
P356
10.1158/1535-7163.MCT-13-0065
P577
2013-04-02T00:00:00Z